News & Presentations

Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
July 27, 2021

Seattle, Wash., July 27, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointments of three new hires in the company’s research and business development functions, including Bruce Kerwin, Ph.D. as Senior Vice President of Process and Product Development, Ryan Larson, Ph.D. as Vice President and Head of Translational Science, and Mike Fitzpatrick as Vice President of Business Development and Operations.

READ MORE >

Umoja Biopharma Closes an Oversubscribed $210 Million Series B Financing to Expand Integrated Immunotherapy Platforms and Advance Programs to the Clinic
June 15, 2021

Seattle, Wash., June 15, 2021 – Umoja Biopharma, an oncology company leveraging its proprietary integrated technologies to reprogram immune cells in vivo to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the completion of an oversubscribed $210 million Series B financing.

READ MORE >

Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
June 8, 2021

Seattle, WA, June 8, 2021– Umoja Biopharma, a leading oncology company leveraging its proprietary, integrated technologies to reprogram immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and hematologic malignancies, today announced the appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer.

READ MORE >

Umoja Biopharma Announces Appointment of Dr. Irena Melnikova as Chief Financial Officer
May 18, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Irena Melnikova, Ph.D., as Chief Financial Officer.

READ MORE >

Umoja Biopharma Appoints Renowned Oncologist and Industry Leader Dr. Nushmia Khokhar as Chief Medical Officer
April 6, 2021

Umoja Biopharma, a biotechnology company pioneering an integrated, in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar, M.D., as Chief Medical Officer.

READ MORE >

We are led by a world class team that operates on a foundation of respect for the contributions of everyone on the Umoja team.